BIOCRYST PHARMACEUTICALS, INC. (BCRX) Free cash flow 2016–2025
BIOCRYST PHARMACEUTICALS, INC. (BCRX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$344.9MFY2025 · since FY2016: -$58.7M → $344.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $344.9M | +749.0% |
| FY2024 | -$53.1M | +45.4% |
| FY2023 | -$97.3M | +40.4% |
| FY2022 | -$163.2M | -12.9% |
| FY2021 | -$144.5M | -6.6% |
| FY2020 | -$135.6M | -50.8% |
| FY2019 | -$89.9M | +3.2% |
| FY2018 | -$92.9M | -124.1% |
| FY2017 | -$41.5M | +29.4% |
| FY2016 | -$58.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice